Peter Nash
0000-0002-2571-788X
Griffith University
193 papers found
Refreshing results…
Prolonged exposure to subcutaneous and intravenous abatacept in patients with rheumatoid arthritis does not affect rates of infection, malignancy and autoimmune events: results from pooled clinical trial data
Impact of etanercept-methotrexate therapy on patient-reported outcomes in moderately active rheumatoid arthritis: Australian results from the induction period of preserve trial
Long-term safety of tocilizumab in rheumatoid arthritis clinical trials
Analysis of the Validation Status of Quality of Life and Functional Disability Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Results of a Systematic Literature Analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS)
Subcutaneous Abatacept vErsus Intravenous Abatacept: A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort
Mortality and Causes of Death in an Australian Systemic Sclerosis Cohort
The Efficacy and Safety of Subcutaneous (Sc) Abatacept (Aba) With or Without MTX in Patients With Active Ra
The Efficacy and Safety of Subcutaneous (Sc) Abatacept (Aba) Is Consistent With the Established Intravenous (Iv) Profile in a Study of 1457 Patients With Ra and an Inadequate Response to MTX (Mtx-Ir)
Frequency, Clinical Characteristics and Risk Factors for Digital Ulcers in Systemic Sclerosis
Efficacy, safety and pharmacokinetics of subcutaneous abatacept in patients with rheumatoid arthritis, with or without an intravenous (IV) loading dose
Efficacy and safety of subcutaneous recombinant chaperonin10 in patients with active rheumatoid arthritis despite methotrexate treatment
Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed
Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: A 24-Month Phase 3 Study
Impact of Etanercept-Methotrexate Therapy on Disease Activity in Moderately Active Rheumatoid Arthritis: Interim Overall and Australian Results From the Preserve Trial
Achievement of low disease activity or remission with etanercept-methotrexate therapy in subjects with moderately active rheumatoid arthritis: preliminary results from the preserve trial
Safety profile of subcutaneous abatacept focusing on clinically relevant events in patients with rheumatoid arthritis (RA) and up to 4.5 years of exposure
Safety and Tolerability of Tocilizumab in Long-Term Extension Studies of Rheumatoid Arthritis
Registries in systemic sclerosis: a worldwide experience
Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in australian patients: A cross-sectional, multicenter study
Missing publications? Search for publications with a matching author name.